Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 6/20 | 0.57 |
| ▸ | DPP4 | P27487 | 1/20 | 0.38 |
| ▸ | KARS1 | Q15046 | 3/20 | 0.38 |
| ▸ | WNT3A | P56704 | 1/20 | 0.36 |
| ▸ | PRKD1 | Q15139 | 1/20 | 0.36 |
| ▸ | CCNT1 | O60563 | 2/20 | 0.36 |
| ▸ | CDK9 | P50750 | 2/20 | 0.36 |
| ▸ | CDK4 | P11802 | 1/20 | 0.36 |
| ▸ | CCND1 | P24385 | 1/20 | 0.36 |
| ▸ | CCND3 | P30281 | 1/20 | 0.36 |
| ▸ | CDK6 | Q00534 | 1/20 | 0.36 |
| ▸ | PRKCH | P24723 | 1/20 | 0.34 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.34 |
| ▸ | MAP3K12 | Q12852 | 1/20 | 0.34 |
| ▸ | KDR | P35968 | 1/20 | 0.33 |
| ▸ | MAPK10 | P53779 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14673640 | 0.90 | SYK (0.53) | SYKDPP4KARS1WNT3APRKD1 | |
| SCHEMBL14673934 | 0.87 | SYK (0.51) | SYKDPP4KARS1WNT3A | |
| SCHEMBL2289490 | 0.85 | SYK (0.53) | SYKDPP4KARS1WNT3APRKD1 | |
| SCHEMBL14680991 | 0.84 | SYK (0.51) | SYKDPP4KARS1KDR | |
| SCHEMBL12519250 | 0.83 | SYK (0.47) | SYKDPP4KARS1WNT3APRKD1 | |
| SCHEMBL2355999 | 0.81 | SYK (0.46) | SYKDPP4KARS1WNT3APRKD1 | |
| SCHEMBL2225041 | 0.81 | KARS1 (0.53) | SYKDPP4KARS1MAP3K12 | |
| SCHEMBL2225729 | 0.76 | SYK (0.48) | SYKKARS1CCNT1CDK9CDK4 | |
| SCHEMBL14674163 | 0.75 | SYK (0.53) | SYKCCNT1CDK9CDK4CCND1 | |
| SCHEMBL14673493 | 0.74 | SYK (0.48) | SYKPRKD1KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8962665-B2 | Thiazole and oxazole kinase inhibitors | AB SCIENCE (FR) | 2015-02-24 | — | — | US | disclosed |
| US-20130035331-A1 | THIAZOLE AND OXAZOLE KINASE INHIBITORS | AB SCIENCE (FR) | 2013-02-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130035331-A1 | THIAZOLE AND OXAZOLE KINASE INHIBITORS | SYK, LTK, MERTK | SYK 1/4885DPP4 1544/4885KARS1 1099/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.